Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4, Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to SeptemberÂ
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Revenue of $3.14M
March 9, 2022 4:05 PM ESTMirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 revenue of $3.14 million, versus $0 reported last year.
Expect at least $8.0 million in LIVMARLI net product sales in first quarter 2022.
For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.
... More